Infinity Pharmaceuticals Inc.
780 Memorial Drive
Cambridge
Massachusetts
02139
United States
Tel: 617-453-1000
Fax: 617-453-1001
Website: http://www.infi.com/
Email: info@infi.com
About Infinity Pharmaceuticals Inc.
The mission of Infinity Pharmaceuticals, Inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation.Small molecule discovery and development capabilities Infinity’s programs arise from the integration of a broad range of research and development capabilities, including strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation.
Strategic alliances Building on its strengths in innovative small molecule drug discovery and development, Infinity has established significant alliances with leading pharmaceutical and biotechnology companies to help realize the full potential of its product pipeline.
Business and scientific expertise The company has assembled a team of passionate, committed, and innovative individuals who bring together their collective expertise in all areas of business and drug discovery and development.
Culture of Citizen-Ownership Infinity’s culture and environment of Citizen-Ownership is as important as its technologies. Infinity works together as a community with the shared goal of bringing important new medicines to patients.
466 articles about Infinity Pharmaceuticals Inc.
-
Infinity Pharmaceuticals, Inc. and MedImmune, Inc. Announce Approval for Generic Name for Novel Hsp90 Inhibitor
2/4/2008
-
Infinity Pharmaceuticals, Inc. Reviews 2007 Achievements and Announces 2008 Goals
1/7/2008
-
Infinity Pharmaceuticals, Inc. Announces Updated Presentation Time At the JPMorgan Healthcare Conference
1/4/2008
-
Infinity Pharmaceuticals, Inc. and MedImmune, Inc. Initiate Phase 1b Trial of IPI-504 in Combination With Taxotere in Patients With Advanced Solid Tumor Cancers
1/4/2008
-
Infinity Pharmaceuticals, Inc. to Present At the 2008 JPMorgan Healthcare Conference
12/17/2007
-
Infinity Pharmaceuticals, Inc. and MedImmune, Inc. Initiate Phase 2 Clinical Trial of IPI-504, a Novel Hsp90 Inhibitor, in Patients With Advanced Hormone-Refractory Prostate Cancer
11/13/2007
-
Infinity Pharmaceuticals, Inc. Announces Hedgehog Pathway Inhibitor Agreement With AstraZeneca PLC
11/12/2007
-
Infinity Pharmaceuticals, Inc. to Present At Acumnet Biofin Rodman & Renshaw Healthcare Conference
10/30/2007
-
Infinity Pharmaceuticals, Inc. Announces Advancement of Lead Development Program and Third Quarter Financial Results
10/30/2007
-
Infinity Pharmaceuticals, Inc. and MedImmune, Inc. Present Preliminary Phase 1 Data Demonstrating Biological Activity of IPI-504, A Novel Hsp90 Inhibitor, in Advanced Non-Small Cell Lung Cancer
10/25/2007
-
Infinity Pharmaceuticals, Inc. Announces Conference Call Discussing Third Quarter 2007 Results
10/23/2007
-
Infinity Pharmaceuticals, Inc. and MedImmune, Inc. Announce Issuance of U.S. Patent for Proprietary Heat Shock Protein 90 Inhibitors
10/23/2007
-
Infinity Pharmaceuticals, Inc. to Present at 2007 Biotechnology Industry Organization (BIO) Investor Forum
10/3/2007
-
Infinity Pharmaceuticals, Inc. to Present At UBS Warburg Global Life Sciences Conference
9/19/2007
-
Infinity Pharmaceuticals, Inc. and MedImmune, Inc. Receive Orphan Drug Designation for IPI-504 for Treatment of Gastroinstestinal Stromal Tumors
9/17/2007
-
Infinity Pharmaceuticals, Inc. Announces Conference Call Discussing Second Quarter 2007 Results
7/27/2007
-
Infinity Pharmaceuticals, Inc. to Present At Jefferies Healthcare Conference
6/22/2007
-
Infinity Pharmaceuticals, Inc. to Present At Needham Biotechnology & Medical Technology Conference
6/7/2007
-
Infinity Pharmaceuticals, Inc. and MedImmune, Inc. Present Updated Phase I Results of IPI-504 in GIST at American Society of Clinical Oncology Annual Meeting
6/5/2007
-
Infinity Pharmaceuticals, Inc. and MedImmune, Inc. Announce Updated Data On IPI-504 to be Presented At American Society of Clinical Oncology
5/31/2007